TRACKING / TRIAL TRACKER
Neoantigen vaccine clinical trials tracker
A structured view of active and notable neoantigen-vaccine programs — phase, sponsor, and status — refreshed as registries change.
A live view of neoantigen and personalized-cancer-vaccine clinical trials — who is sponsoring them, what phase and status each is in, the indication, and when the registry record was last touched. The table is auto-refreshed daily straight from ClinicalTrials.gov.
No neoantigen vaccine is approved anywhere yet — every program below is investigational, and inclusion here is not an endorsement or a claim of efficacy. For background, see the Primer and the companies landscape.
106trials tracked5in Phase 350recruiting7featured
A maintained tracker, not a static reference — rows refresh as ClinicalTrials.gov records change. Featured (★) rows mark the furthest-advanced or most closely watched programs; sort or filter the table below to focus on phase, sponsor, or recruiting status.
Status
Phase
| Program / Title | Sponsor | Phase | Status | Indication | Primary completion | Last update |
|---|---|---|---|---|---|---|
| ★ FeaturedA Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)NCT05933577Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — INTerpath-001 adjuvant melanoma, Phase 3 | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 3 | Active Not Recruiting | Melanoma | 2029-10-26 (est.) | 24 Sept 2025 |
| ★ FeaturedA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — INTerpath NSCLC, Phase 3 | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 2030-06-25 (est.) | 26 May 2026 |
| ★ FeaturedA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACNCT05968326Autogene cevumeran (BNT122 / RO7198457), BioNTech + Genentech/Roche — adjuvant program | Genentech, Inc.+ BioNTech SE | Phase 2 | Recruiting | Adenocarcinoma, Pancreatic Ductal | 2031-01-01 (est.) | 11 May 2026 |
| ★ FeaturedA Clinical Trial Evaluating TG4050 in Head and Neck CancerNCT04183166TG4050, Transgene + NEC — adjuvant head & neck cancer | Transgene | Phase 1/2 | Active Not Recruiting | Squamous Cell Carcinoma of Head and Neck | 2027-12-30 (est.) | 16 Jan 2026 |
| ★ FeaturedA Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic MelanomaNCT05309421EVX-01, Evaxion Biotech — with pembrolizumab in advanced melanoma, Phase 2 | Evaxion Biotech A/S+ Merck Sharp & Dohme LLC | Phase 2 | Active Not Recruiting | Melanoma Stage IV, Unresectable Melanoma | 2025-09-30 (est.) | 22 Sept 2025 |
| ★ FeaturedNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsNCT04041310NOUS-209, Nouscom — microsatellite-unstable solid tumors, Phase 1/2 | Nouscom SRL+ Merck Sharp & Dohme LLC | Phase 1/2 | Active Not Recruiting | Solid Tumor, Adult | 2026-10-30 (est.) | 13 Feb 2026 |
| ★ FeaturedGNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCCNCT04251117GNOS-PV02, Geneos Therapeutics — with INO-9012 + pembrolizumab in advanced HCC, Phase 1/2 | Geneos Therapeutics | Phase 1/2 | Active Not Recruiting | HCC | 2024-11-29 | 22 Apr 2026 |
| Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant TherapyNCT07612930 | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | — | Available | Pancreatic Ductal Adenocarcinoma (PDAC) | — | 29 May 2026 |
| A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.NCT03219450 | Dana-Farber Cancer Institute+ 3 | Phase 1 | Recruiting | Lymphocytic Leukemia | 2027-07-31 (est.) | 28 May 2026 |
| Preventive Dendritic Cell Vaccination for Lynch Syndrome CarriersNCT07609901 | Radboud University Medical Center+ Dutch National Health Care Institute | Phase 3 | Not Yet Recruiting | Lynch Syndrome | 2032-10-01 (est.) | 27 May 2026 |
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast CancerNCT06631092 | NEC Bio B.V+ NEC Bio Therapeutics | Phase 1/2 | Recruiting | Triple Negative Breast Cancer | 2027-12-31 (est.) | 26 May 2026 |
| To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsNCT07594964 | Shenzhen Xinhe Biomedical | Phase 1 | Recruiting | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC) | 2029-10-30 (est.) | 19 May 2026 |
| Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic CancerNCT07587827 | Centre Georges Francois Leclerc | Phase 1 | Not Yet Recruiting | Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer | 2027-05-01 (est.) | 14 May 2026 |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerNCT03606967 | National Cancer Institute (NCI) | Phase 2 | Recruiting | Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | 2026-12-30 (est.) | 13 May 2026 |
| YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate CancerNCT07583160 | Changhai Hospital | Phase 1 | Enrolling By Invitation | Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC) | 2028-06-01 (est.) | 13 May 2026 |
| Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid TumorsNCT07560943 | West China Hospital | Phase 1 | Recruiting | Cancer | 2027-04-28 (est.) | 11 May 2026 |
| Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated GlioblastomaNCT04015700 | Washington University School of Medicine+ 3 | Phase 1 | Active Not Recruiting | Glioblastoma | 2022-05-13 | 7 May 2026 |
| Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System TumorsNCT03988283 | Washington University School of Medicine+ Children's Discovery Institute | Phase 1 | Recruiting | Pediatric Recurrent Central Nervous System Tumors | 2029-03-31 (est.) | 7 May 2026 |
| Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer PatientsNCT07300475 | Washington University School of Medicine | Phase 1 | Not Yet Recruiting | Triple Negative Breast Cancer | 2030-04-08 (est.) | 7 May 2026 |
| QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.NCT03552718 | NantBioScience, Inc. | Phase 1 | Completed | Colorectal Cancer, Breast Cancer | 2025-03-18 | 7 May 2026 |
| Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to SurgeryNCT05111353 | Washington University School of Medicine+ 4 | Phase 1 | Completed | Pancreas Cancer, Pancreatic Cancer | 2025-11-03 | 6 May 2026 |
| A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)NCT07430202 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ 3 | Phase 1 | Not Yet Recruiting | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | 2030-08 (est.) | 6 May 2026 |
| Preventive Dendritic Cell Vaccination for Lynch SyndromeNCT07412197 | Radboud University Medical Center+ Dutch Cancer Society | Phase 1/2 | Not Yet Recruiting | Lynch Syndrome | 2029-12 (est.) | 6 May 2026 |
| Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After SurgeryNCT04968366 | Beijing Tiantan Hospital+ ZhongSheng BioTech Inc. | Phase 1 | Completed | Glioblastoma Multiforme of Brain | 2024-04-30 | 4 May 2026 |
| Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaNCT05743595 | Washington University School of Medicine+ 3 | Phase 1 | Active Not Recruiting | Unmethylated Glioblastoma | 2026-04-07 | 4 May 2026 |
| Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance TherapyNCT07551037 | Fujian Medical University Union Hospital | Phase 1 | Recruiting | Acute Myeloid Leukemia, Personalized Active Immunotherapy | 2026-09-01 (est.) | 1 May 2026 |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerNCT02600949 | M.D. Anderson Cancer Center+ National Cancer Institute (NCI) | Phase 1 | Recruiting | Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | 2027-05-31 (est.) | 24 Apr 2026 |
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabNCT04266730 | UNC Lineberger Comprehensive Cancer Center | Phase 1 | Suspended | Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | 2027-06-01 (est.) | 23 Apr 2026 |
| Personalized Neoantigen Cancer Vaccine for Patients With Solid TumorsNCT06614140 | Seqker Biosciences, Inc. | Phase 1/2 | Completed | Cancer, Solid Tumor, Adult | 2025-08-15 | 22 Apr 2026 |
| Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMNCT02287428 | Dana-Farber Cancer Institute+ 4 | Phase 1 | Active Not Recruiting | Glioblastoma | 2027-02 (est.) | 17 Apr 2026 |
| KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic CancerNCT07353645 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1/2 | Recruiting | Colorectal Cancer, Pancreatic Cancer | 2029-01-01 (est.) | 15 Apr 2026 |
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)NCT06141369 | Shanghai Jiao Tong University School of Medicine | Phase NA | Recruiting | Adrenal Cortical Carcinoma, Medullary Thyroid Cancer | 2026-12-30 (est.) | 9 Apr 2026 |
| A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid TumorNCT06682117 | Fudan University | Phase NA | Recruiting | Treatment, Neoantigen | 2026-12-30 (est.) | 2 Apr 2026 |
| Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant TherapyNCT06435351 | H. Lee Moffitt Cancer Center and Research Institute | Phase EARLY_PHASE1 | Recruiting | Breast Cancer, Triple Negative Breast Cancer | 2029-05 (est.) | 1 Apr 2026 |
| Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular LymphomaNCT03361852 | Dana-Farber Cancer Institute | Phase 1 | Active Not Recruiting | Follicular Lymphoma | 2026-12-31 (est.) | 25 Mar 2026 |
| NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaNCT04930783 | Dana-Farber Cancer Institute+ Celldex Therapeutics | Phase 1 | Active Not Recruiting | Melanoma, Metastatic Melanoma | 2027-12-31 (est.) | 25 Mar 2026 |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced CancersNCT03568058 | Aaron Miller | Phase 1 | Completed | Advanced Cancer | 2022-12-12 | 24 Mar 2026 |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGNCT04943848 | Ann & Robert H Lurie Children's Hospital of Chicago+ 3 | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | 2026-09 (est.) | 17 Mar 2026 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 | Mayo Clinic | Phase 1/2 | Recruiting | Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 2028-03-31 (est.) | 12 Mar 2026 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerNCT05098210 | Fred Hutchinson Cancer Center+ Amazon, Inc. | Phase 1 | Recruiting | Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | 2027-11-01 (est.) | 12 Mar 2026 |
| Cancer Preventive Vaccine Nous-209 for Lynch Syndrome PatientsNCT05078866 | National Cancer Institute (NCI) | Phase 1/2 | Active Not Recruiting | Colorectal Carcinoma, Lynch Syndrome | 2025-04-16 | 3 Mar 2026 |
| Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric CancerNCT07298200 | Jia Wei+ NeoCura | Phase 1 | Recruiting | Advanced Gastric Cancer | 2028-06 (est.) | 25 Feb 2026 |
| A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric GliomaNCT06342908 | Jonsson Comprehensive Cancer Center | Phase 1 | Active Not Recruiting | Diffuse Hemispheric Glioma, H3 G34-Mutant | 2027-03-08 (est.) | 17 Feb 2026 |
| XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic CancerNCT06353646 | Wu Wenming+ NeoCura | Phase NA | Recruiting | Pancreatic Cancer | 2026-06 (est.) | 13 Feb 2026 |
| Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal CancerNCT07329894 | Beijing GoBroad Hospital+ NeoCura | Phase 1 | Recruiting | Gastrointestinal Cancer | 2027-08 (est.) | 12 Feb 2026 |
| Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical ResectionNCT07368803 | Yifan Wang+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1/2 | Recruiting | Biliary Malignant Tumors | 2027-09-30 (est.) | 3 Feb 2026 |
| NeoVax Plus Ipilimumab in Renal Cell CarcinomaNCT02950766 | Patrick Ott, MD, PhD+ 2 | Phase 1 | Active Not Recruiting | Kidney Cancer | 2027-12-31 (est.) | 3 Feb 2026 |
| Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed GlioblastomaNCT07365280 | ZSky Biotech Inc | Phase 2 | Not Yet Recruiting | Glioblastoma | 2028-12-24 (est.) | 26 Jan 2026 |
| A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid TumorsNCT05741242 | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | Phase 1/2 | Enrolling By Invitation | Cancer, Solid Tumor | 2027-01 (est.) | 15 Jan 2026 |
| Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid TumorsNCT06963697 | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | — | Available | Cancer | — | 15 Jan 2026 |
| Clinical Study of XP-006 mRNA Vaccine for R/R B-NHLNCT07334574 | Ruijin Hospital+ Shanghai Xinpu BioTechnology Company Limited | Phase 1 | Not Yet Recruiting | B-cell Non-Hodgkin's Lymphoma (B-NHL) | 2028-01-01 (est.) | 13 Jan 2026 |
| Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual DiseaseNCT06529822 | Washington University School of Medicine+ Natera, Inc. | Phase 1 | Recruiting | Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma | 2028-10-31 (est.) | 13 Jan 2026 |
| COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal CancerNCT07328087 | Biogenea Pharmaceuticals Ltd.+ Interbalkan Medical Center, Thessaloniki, Greece | Phase EARLY_PHASE1 | Recruiting | Colorectal Cancer Metastatic, Colorectal Cancer Stage III | 2030-12-02 (est.) | 9 Jan 2026 |
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid TumorsNCT06631079 | NEC Bio B.V+ NEC Bio Therapeutics | Phase 1/2 | Active Not Recruiting | Solid Tumor | 2026-07-31 (est.) | 8 Jan 2026 |
| Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With SurgeryNCT04161755 | Memorial Sloan Kettering Cancer Center+ 2 | Phase 1 | Active Not Recruiting | Pancreatic Cancer | 2026-11-11 (est.) | 7 Jan 2026 |
| GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial CancerNCT07316361 | Biogenea Pharmaceuticals Ltd. | Phase EARLY_PHASE1 | Enrolling By Invitation | Endometrial Carcinoma, Endometrial Carcinoma Stage III | 2029-12-02 (est.) | 7 Jan 2026 |
| Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaNCT03929029 | Dana-Farber Cancer Institute+ National Cancer Institute (NCI) | Phase 1 | Active Not Recruiting | Cutaneous Melanoma | 2022-12-27 | 5 Jan 2026 |
| A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaNCT01970358 | Patrick Ott, MD, PhD | Phase 1 | Completed | Melanoma | 2015-09 | 29 Dec 2025 |
| Ex Vivo Expansion (ACT-X)NCT07137312 | Mayo Clinic | — | Recruiting | Solid Tumor, Healthy | 2028-10 (est.) | 23 Dec 2025 |
| Personalized Vaccine in Treating Patients With Smoldering Multiple MyelomaNCT03631043 | M.D. Anderson Cancer Center | Phase EARLY_PHASE1 | Completed | Smoldering Plasma Cell Myeloma | 2025-12-10 | 19 Dec 2025 |
| Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung CancerNCT07285434 | Biogenea Pharmaceuticals Ltd.+ https://interonco.gr/en/ | Phase EARLY_PHASE1 | Enrolling By Invitation | NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification | 2028-02-02 (est.) | 16 Dec 2025 |
| LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung CancerNCT05886439 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1/2 | Recruiting | Lung Cancer | 2027-05-30 (est.) | 8 Dec 2025 |
| Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.NCT07077616 | Biogenea Pharmaceuticals Ltd.+ Naval Hospital, Athens | Phase EARLY_PHASE1 | Recruiting | Glioma | 2027-12-01 (est.) | 8 Dec 2025 |
| DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaNCT04248569 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ Fibrolamellar Cancer Foundation | Phase 1 | Recruiting | Fibrolamellar Hepatocellular Carcinoma (FLC) | 2029-03-01 (est.) | 3 Dec 2025 |
| An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)NCT03897881 | ModernaTX, Inc.+ Merck Sharp & Dohme LLC | Phase 2 | Active Not Recruiting | Melanoma | 2032-11-30 (est.) | 3 Dec 2025 |
| Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerNCT04117087 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ 3 | Phase 1 | Active Not Recruiting | Colorectal Cancer, Pancreatic Cancer | 2027-06-01 (est.) | 3 Dec 2025 |
| Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerNCT05013216 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ 2 | Phase 1 | Recruiting | High Risk Cancer, Pancreatic Cancer | 2027-10-01 (est.) | 3 Dec 2025 |
| Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical ResectionNCT05307835 | Second Affiliated Hospital, School of Medicine, Zhejiang University+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1 | Active Not Recruiting | Resectable Esophageal Cancer | 2026-06-30 (est.) | 2 Dec 2025 |
| Personalized Neoantigen Peptide Vaccines for Solid TumorsNCT07002203 | Seqker Biosciences, Inc.+ Bumrungrad International Hospital | Phase 1/2 | Recruiting | Solid Tumors, Advanced Cancer | 2027-08 (est.) | 1 Dec 2025 |
| CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid TumorsNCT05631899 | Chinese PLA General Hospital+ Zhejiang University | Phase 1 | Active Not Recruiting | Solid Tumor, Adult, EphA2 Overexpression | 2026-06-30 (est.) | 24 Nov 2025 |
| Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic CancerNCT06496373 | Ruijin Hospital+ Shanghai Xinpu BioTechnology Company Limited | Phase EARLY_PHASE1 | Recruiting | Pancreatic Cancer Resectable, Chemotherapy-intolerant | 2026-06-30 (est.) | 17 Nov 2025 |
| Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerNCT04397003 | Washington University School of Medicine+ 2 | Phase 2 | Active Not Recruiting | Extensive-stage Small Cell Lung Cancer | 2027-09-30 (est.) | 22 Oct 2025 |
| Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCNCT04912765 | National Cancer Centre, Singapore+ Bristol-Myers Squibb | Phase 2 | Recruiting | Hepatocellular Carcinoma, Hepatocellular Cancer | 2026-12 (est.) | 23 Sept 2025 |
| Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid TumorsNCT07182435 | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Phase EARLY_PHASE1 | Not Yet Recruiting | Solid Tumor Malignancies | 2028-12-31 (est.) | 19 Sept 2025 |
| Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular CarcinomaNCT07123545 | Zhejiang University+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1/2 | Recruiting | Advanced Hepatocellular Carcinoma (HCC) | 2027-07-31 (est.) | 14 Aug 2025 |
| XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic CancerNCT07114666 | Peking Union Medical College Hospital | Phase NA | Not Yet Recruiting | Pancreatic Cancer | 2029-08 (est.) | 11 Aug 2025 |
| A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative NeoplasmsNCT05444530 | Janssen Research & Development, LLC+ Bristol-Myers Squibb | Phase 1 | Completed | Myeloproliferative Neoplasms | 2025-06-24 | 20 Jul 2025 |
| Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor TreatmentNCT07067385 | Ruijin Hospital+ 2 | Phase 1 | Recruiting | Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy, Gastrointestinal Tumors | 2027-12-31 (est.) | 16 Jul 2025 |
| Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)NCT05685004 | TVAX Biomedical | Phase 2/3 | Active Not Recruiting | Glioblastoma Multiforme of Brain | 2026-12 (est.) | 1 Jul 2025 |
| NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid TumorsNCT05354323 | NEC OncoImmunity AS | Phase 1 | Active Not Recruiting | Solid Tumors, Adult | 2025-12-31 (est.) | 26 Jun 2025 |
| Personalized Vaccine for TNBC ImmunotherapyNCT06195618 | Universidad Nacional de Colombia+ Fundación Salud de los Andes | Phase 1 | Not Yet Recruiting | Breast Cancer Female | 2027-06-01 (est.) | 25 Jun 2025 |
| NeoVax With Nivolumab in Patients With Ovarian CancerNCT04024878 | Dana-Farber Cancer Institute+ United States Department of Defense | Phase 1 | Active Not Recruiting | Ovarian Cancer | 2025-04-30 | 18 Jun 2025 |
| Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine GliomaNCT04749641 | Yang Zhang+ TCRCure Biopharma Ltd. | Phase 1 | Completed | Diffuse Intrinsic Pontine Glioma | 2024-10-14 | 6 Jun 2025 |
| Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid TumorsNCT06577532 | Ruijin Hospital+ Suzhou Abogen Biosciences Co., Ltd. | Phase EARLY_PHASE1 | Recruiting | Pancreatic Neoplasms, Other Solid Tumors | 2026-12 (est.) | 21 May 2025 |
| XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid LeukemiaNCT06980155 | Shanghai Jiao Tong University School of Medicine+ Shanghai Xinpu BioTechnology Company Limited | Phase EARLY_PHASE1 | Recruiting | Acute Myeloid Leukemia | 2027-01-30 (est.) | 20 May 2025 |
| A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerNCT05141721 | Seattle Project Corporation | Phase 2/3 | Active Not Recruiting | Colorectal Neoplasms | 2027-03 (est.) | 16 May 2025 |
| Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical ResectionNCT06406816 | Yongyi Zeng | Phase EARLY_PHASE1 | Recruiting | Intrahepatic Cholangiocarcinoma | 2026-05 (est.) | 15 May 2025 |
| An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor TreatmentNCT06497010 | The Affiliated Hospital Of Guizhou Medical University+ Innovac Therapeutics | Phase EARLY_PHASE1 | Recruiting | Advanced Solid Tumor | 2026-07 (est.) | 1 May 2025 |
| MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung CancerNCT04078269 | University Hospital, Ghent+ 2 | Phase 1 | Completed | Non-small Cell Lung Cancer | 2024-02-01 | 29 Apr 2025 |
| A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDACNCT06913218 | Akeso+ Fudan University | Phase 1 | Not Yet Recruiting | Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma | 2028-02-23 (est.) | 6 Apr 2025 |
| Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSINCT01885702 | Radboud University Medical Center | Phase 1/2 | Unknown | Colorectal Cancer | 2016-04 | 4 Apr 2025 |
| Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid TumorsNCT05916248 | Ruijin Hospital+ Shanghai Xinpu BioTechnology Company Limited | Phase EARLY_PHASE1 | Recruiting | Advanced Solid Tumor | 2026-06-30 (est.) | 1 Apr 2025 |
| Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)NCT06314087 | The University of Hong Kong-Shenzhen Hospital | Phase 2 | Recruiting | Advanced Tumors | 2026-08-16 (est.) | 25 Mar 2025 |
| Nous-PEV: a Novel Immunotherapy for Lung Cancer and MelanomaNCT04990479 | Nouscom SRL | Phase 1 | Terminated | Melanoma (Skin), Non-Small-Cell Lung Carcinoma | 2024-03-05 | 20 Mar 2025 |
| Personalized DC Vaccine for Postoperative CancerNCT04147078 | Sichuan University | Phase 1 | Recruiting | Gastric Cancer, Hepatocellular Carcinoma | 2025-12-31 (est.) | 28 Feb 2025 |
| Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic CancerNCT06344156 | Sichuan University | Phase 1 | Recruiting | Pancreatic Cancer, Adjuvant Therapy | 2026-04-01 (est.) | 28 Feb 2025 |
| Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid TumorsNCT05749627 | The First Affiliated Hospital of Nanchang University+ Shanghai Dengding BioAI Co. | Phase NA | Recruiting | Advanced Malignant Solid Tumors | 2025-12-31 (est.) | 27 Feb 2025 |
| Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade GliomasNCT06253234 | Beijing Tiantan Hospital+ ZhongSheng BioTech Inc. | Phase 1 | Recruiting | WHO Grade III Gliomas, WHO Grade IV Gliomas | 2025-06-30 (est.) | 11 Feb 2025 |
| Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal CancerNCT06522919 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 | Recruiting | Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma | 2026-04-01 (est.) | 28 Jan 2025 |
| Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon CancerNCT05456165 | Gritstone bio, Inc. | Phase 2 | Withdrawn | Colonic Neoplasms, Colorectal Neoplasms | 2022-09-01 | 31 Dec 2024 |
| Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line TreatmentNCT06751849 | The First Affiliated Hospital of Nanchang University | Phase 2 | Recruiting | Advanced NSCLC | 2026-03-10 (est.) | 30 Dec 2024 |
| Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line TreatmentNCT06751966 | The First Affiliated Hospital of Nanchang University | Phase NA | Recruiting | Colorectal Cancer (CRC) | 2026-08-31 (est.) | 30 Dec 2024 |
| Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line TreatmentNCT06751953 | The First Affiliated Hospital of Nanchang University | Phase NA | Recruiting | Colorectal Cancer (CRC) | 2026-08-31 (est.) | 30 Dec 2024 |
| Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line TreatmentNCT06751914 | The First Affiliated Hospital of Nanchang University | Phase NA | Recruiting | Colorectal Cancer (CRC) | 2026-08-31 (est.) | 30 Dec 2024 |
| Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line TreatmentNCT06751940 | The First Affiliated Hospital of Nanchang University | Phase NA | Recruiting | Colorectal Cancer (CRC) | 2026-08-31 (est.) | 30 Dec 2024 |
| Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line TreatmentNCT06752057 | The First Affiliated Hospital of Nanchang University | Phase NA | Recruiting | Advanced NSCLC | 2026-08-31 (est.) | 30 Dec 2024 |
FAQ
Is there an approved neoantigen vaccine?
No. As of today every neoantigen and personalized-cancer-vaccine program is investigational — none is approved by the FDA, EMA, or any major regulator. The furthest-advanced candidates are in Phase 3.
What phase is mRNA-4157 / intismeran autogene in?
Phase 3. The Moderna–Merck personalized neoantigen mRNA vaccine (mRNA-4157, intismeran autogene) is being tested with pembrolizumab in the INTerpath-001 trial as adjuvant therapy for resected high-risk melanoma, with additional Phase 3 indications underway.
How current is this tracker?
It is auto-refreshed daily from the ClinicalTrials.gov v2 API. The exact build time is shown as the last-updated date at the top of this page; each refresh re-pulls sponsor, phase, status, and last-update fields directly from the registry.
Where does this data come from?
ClinicalTrials.gov — the U.S. National Library of Medicine's public registry of clinical studies. Every row links to its source study record so you can verify the details and read the full protocol summary.